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Replacing hormone therapyVis the decline in prescribing sustained,
and are nonhormonal drugs substituted?
Stefan Vegter, BSc, Pieternel Ko¨lling, MD, Marjolijn To¨ben, MSc, Sipke T. Visser, MSc,
and Lolkje T.W. de Jong-van den Berg, PharmD, PhD
Abstract
Objectives: After two cautioning landmark studies in 2002 and 2003, a dramatic decrease in hormonal therapy
(HT) prescribing for menopausal symptoms was seen. Our objectives were to (1) determine whether this decline in
HT prescribing sustained until 2007 and (2) investigate nonhormonal drug prescribing for women who stopped HT.
Methods: We analyzed drug dispensing data from community pharmacies in The Netherlands. For the first
objective, we analyzed exposure prevalence of HT. For our second objective, we selected all women who were
dispensed HT prescriptions between August 2002 and August 2003. From this study cohort, we defined our index
group as all women who stopped HT shortly after the studies (n = 1,254) and a reference group as all women who
continued HT (n = 839). We calculated the incidence of nonhormonal therapies for both groups, reporting risk ratio
(RR) and 95% CI. Kaplan-Meier curves were also constructed.
Results: Mean exposure prevalence of HT (per 1,000 women) pre 2002 versus post 2004 was 30.6 versus 15.3
(50.0% decline) for 40 to 49 years, 79.2 versus 25.5 (67.7% decline) for 50 to 59 years, and 28.4 versus 11.6
(59.1% decline) for 60 to 69 years. HT exposure remained low until 2007. HT stoppers receive more clonidine, RR
3.48 (2.36-5.13); anxiolytics or sedatives, RR 1.46 (1.15-1.87); and osteoporosis prophylaxis and treatment, RR
2.04 (1.14-3.66). Young stoppers (40-49 y) received more antidepressants, RR 2.70 (1.41-5.11), whereas older
stoppers (60-69 y) received less antidepressants, RR 0.43 (0.18-1.05). Kaplan-Meier curves showed that
nonhormonal drug prescribing occurred soon after HT was stopped.
Conclusions: This study shows the dramatic and sustained impact of the cautioning landmark studies on HT
prescribing. HT stoppers received more nonhormonal therapies for menopausal symptoms compared with those
who continued HT.
Key Words: Hormone therapy Y Menopause Y Prescribing Y Psychotropic drugs.
H
ormone therapy (HT) has been used for many years
to alleviate menopausal symptoms.1 In 1998, the
Heart and Estrogen/Progestin Replacement Study
(HERS) concluded that HT offered no protection for car-
diovascular events in postmenopausal users with established
coronary disease.2 Still, a 2001 review concluded that HT
was effective in reducing menopausal symptoms, portrayed
only minimal risks for hormone-related cancer (primarily
breast cancer), and reduced the risk for cardiovascular disease.3
Two landmark studies, the Women Health Initiative (WHI)
trial in July 20024 and the observational Million Women
Study (MWS) in August 2003,5 reported severe adverse ef-
fects of HT. The increased risk for breast cancer was con-
firmed, but more novel, HT was found to significantly increase
the risk for coronary heart disease, pulmonary embolism, and
stroke.4,5 In the public6 as well as professional opinion,7,8
these risks of HT outweighed their benefits.
In The Netherlands and most other countries, after the cau-
tioning publications and the subsequent media and professio-
nal attention, a dramatic decrease in HT prescribing occurred.
This decline, as demonstrated by earlier studies from our
group, was most pronounced in the younger age categories,
and in The Netherlands, a larger decline was seen after pub-
lication of the MWS in 2003 compared with the WHI trial
in 2002.9,10
The decline in HT prescribing has led to an increased
interest in nonhormonal therapies for improving menopausal
symptoms.7 Several treatment modalities can be prescribed
for this aim. Two meta-analyses found moderate efficacy in
the treatment of vasomotor symptoms with clonidine, gab-
apentin, and selective serotonin reuptake inhibitors (SSRIs)
or serotonin norepinephrine reuptake inhibitors (SNRIs).11,12
Another meta-analysis found that mood disorders and
depression during menopause could be effectively treated
with several antidepressant drug classes, including tricyclic
antidepressants, SSRIs, and SNRIs, although effectiveness
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might be dependent on age.13 Sleep disorders are commonly
treated with a broad range of psychotropic drugs, primarily
anxiolytics and sedatives.14 Nonhormonal prophylaxis and
treatment of postmenopausal osteoporosis include bisphosph-
onates and calcium and vitamin D supplementation.15 Use of
over-the-counter medication, including complementary and
alternative medicine, is relatively common among postme-
nopausal women.16
The first objective of this study was to determine whether
the decline in HT prescribing in The Netherlands was sus-
tained up until the end of 2006. There is no explicit reason
to suspect that the downward trend in HT has changed since
2003.9 However, reversals in drug-prescribing trends have
been described previously. Furthermore, the Dutch associa-
tion of gynecologists Nederlandse Vereniging voor Obstetrie
en Gynaecologie (NVOG) and the Dutch association of gen-
eral practitioners (Nederlands Huisartsen Genootschap
[NHG]) still maintain, albeit with caution, menopausal symp-
toms as an indication for HT.17,18 Our second objective was
to investigate nonhormonal drug prescribing in women who
stopped HT shortly after the publication of the MWS results in
August 2003Vthe study that evoked the largest decline in
HT prescribing in The Netherlands.9 We hypothesized that
nonhormonal drug prescribing for menopausal symptoms in




We analyzed drug dispensing data from Dutch community
pharmacies using IADB, which holds prescription records of
approximately 500,000 individuals (www.IADB.nl).19,20
In the IADB, each prescription record contains basic patient
characteristics (anonymous identifier, gender, and date of
birth) and medication information on drug name, anatomical
therapeutical chemical code, dosage, and dispensing date.
Commitment of people to their pharmacy has been shown to
be high in The Netherlands,21 ensuring complete medication
histories of individuals. Prescription data between 2002 and
2006 were used for the analyses. Focusing on our two study
objectives, we determined exposure prevalence of HT, based
on prevalence analyses, and nonhormonal therapy substitu-
tion, based on incidence analyses.
Exposure prevalence of HT
We analyzed monthly exposure prevalence of HT be-
tween 2000 and 2007. Population data were obtained from
the Dutch Central Bureau of Statistics. To assess the ef-
fect of the cautioning publications, namely, (1) the WHI
trial in July 20024 and (2) the MWS in August 2003,5 the
publication dates of these studies were indicated. We per-
formed time-trend analyses to determine whether the decline
in HT prescribing was significant. The regression models
FIG. 1. Monthly exposure prevalence of HT, stratified per age category. Publication dates of the two landmark studies are marked with vertical lines.
HT, hormone therapy; WHI, Women’s health Initiative; MWS, Million Women Study.
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included a constant term, a term for linear time trend, and a
binary indicator to indicate HT prescribing from before the
WHI trial versus after the MWS (thus measuring the decline
in HT prescribing).22
HT and nonhormonal therapy
For this study, we defined HT to constitute estrogen plus
progestogen therapy, estrogen-only therapy, progestogen-only
therapy, and the synthetic hormone tibolone. All formulations
were included (oral, transdermal, injections, nasal, implant,
and depot), except vaginal preparations containing estradiol or
estriol, as these are regarded to be without any risk.5
Nonhormonal therapies were selected to include the follow-
ing drug classes: (1) clonidine, (2) gabapentin, (3) antide-
pressants, (4) anxiolytics and sedatives, (5) antipsychotics,
and (6) osteoporosis prophylaxis and treatment. Prescription
records in our data set did not include data on OTC med-
ication, including complementary and alternative medicine,
and we were therefore unable to include these in our analyses.
Study population, index, and reference group
We selected all women aged 40 to 69 years on January 1,
2003, from the IADB. We included only the individuals
known in the database since August 2002 and been dispensed
at least one HT prescription between August 2002 and August
2003. From this study population we selected all women who
stopped HT between August 2003 and January 2004 (index
group) and all women who continued HT at least until July
2004 (reference group). Stopping was defined as not receiving
a prescription for HT for at least 3 months after the stop date
of the last HT prescription. Women, who according to this
definition, stopped before August 2003 or between January
2004 and July 2004, were excluded, although they could later
again receive prescriptions of HT. Finally, women lacking
enough follow-up time (less than 12 months) were excluded.
Analyses
The end date of the last HT prescription was chosen as the
starting point for follow-up in the index group. The mean stop
date was subsequently used as the starting point for follow-up
in the reference group. The incidence rate of drug prescribing
was calculated as the number of incident cases divided by the
total number of patient-days.23 Number of patient-days was
measured from the starting point for follow-up up until either
the prescription date of the nonhormonal drug, the last known
date of that person in the database, or the end of the study
period, whichever occurred first. When calculating the
incidence rate of nonhormonal drug prescribing, women who
were dispensed this drug 1 year before their starting point for
follow-up were not considered, because these women were not
at risk to receive this drug. For example, in the analysis of
antidepressant use, we did not consider women who were
prescribed antidepressants up to 1 year before their starting
point for follow-up; other nonhormonal drug classes, however,
were allowed to be prescribed. We compared the index and
reference groups and calculated incidence risk ratio (IRR)
and 95% CI.23 We performed subanalyses per age category
(40-49 y, 50-59 y, and 60-69 y) and, where appropriate, per
specific type of drug. Univariate survival analysis was
performed by determining Kaplan-Meier (KM) curves. All
statistical analyses were performed using R, version 2.5.1.24
TABLE 1. Population at risk (n), incident cases (Cases), incidence rate (per 100.000 patient-days), and incidence risk ratio (IRR)
with 95% confidence intervals (95% CI) for the different nonhormonal treatment classes
Index (HT stoppers) (total n = 1,254) Reference (HT continuers) (total n = 839)
Treatment class n Cases Incidence rate n Cases Incidence rate IRR (95% CI)
Clonidine
Overall 1,201 143 17.4 816 31 5.0 3.48 (2.36-5.13)
Gabapentin
Overall 1,247 12 1.3 830 11 1.7 0.76 (0.34-1.73)
Antidepressants
Overall 1,046 108 14.5 671 54 10.8 1.34 (0.97-1.86)
Specific drug
TCA 1,046 59 7.7 671 28 5.5 1.40 (0.89-2.20)
SSRI 1,046 43 5.6 671 19 3.7 1.51 (0.88-2.60)
Other 1,046 22 2.8 671 14 2.7 1.04 (0.53-2.03)
Age category
40-49 y 274 34 17.8 262 13 6.6 2.70 (1.42-5.11)
50-59 y 646 66 14.3 328 29 11.8 1.21 (0.78-1.88)
60-69 y 126 8 8.6 81 12 20.0 0.43 (0.18-1.05)
Anxiolytics and sedatives
Overall 839 196 36 558 97 24.6 1.46 (1.15-1.87)
Antipsychotics
Overall 1,232 8 0.9 819 6 0.9 1.00 (0.35-2.88)
Osteoporosis prophylaxis and treatment
Overall 1,184 45 5.1 791 15 2.5 2.04 (1.14-3.66)
Specific drug
Bisphosphonates 1,184 29 3.3 791 8 1.3 2.54 (1.16-5.55)
Calcium 1,184 32 3.6 791 10 1.6 2.25 (1.11-4.58)
Vitamin D 1,184 1 0.1 791 3 0.5 0.20 (0.02-1.92)
HT, hormone therapy; TCA, tricyclic antidepressant; SSRI, selective serotonin reuptake inhibitor.
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A P value of less than 0.05 was deemed to be statistically
significant.
RESULTS
Exposure prevalence of HT
Monthly exposure prevalences of HT are shown in Fig. 1.
The decline in exposure prevalence was modest after publi-
cation of the WHI trial 4, especially for women aged 40 to 49
years and 60 to 69 years. However, a large decline can be
observed in all age categories following publication of the
MWS.5 Exposure prevalence remained low from 2004 until
the end of 2006. Mean exposure prevalence (per 1,000
women) of HT pre 2002 versus post 2004 was 30.6 versus
15.3 (50.0% decline) for women aged 40 to 49 years, 79.2
versus 25.5 (67.7% decline) for 50 to 59 years, and 28.4
versus 11.6 (59.1% decline) for 60 to 69 years. Time-trend
analysis showed that HT prescribing from before the WHI
trial versus after the MWS was significantly reduced in all
age categories (P G 0.001).
Nonhormonal drug prescription
Selection of study population
The IADB held records of 100,523 women aged 40 to 69
years on January 1, 2003, and known in the database since
August 2002. Of those women, we selected all who were
dispensed HT prescriptions between August 2002 and
August 2003, resulting in a total population of 5,721 women
eligible for the study.
Selection of index and reference groups
Our index group comprised 1,254 women who stopped
their HT use between August 2003 and January 2004. Our
FIG. 2. Time to nonhormonal drug prescription for patients who stopped HT (solid line) or continued HT (gray line). A: clonidine; B: anxiolytics or
sedatives; C: osteoporosis prophylaxis. HT, hormone therapy.
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reference group consisted of 839 women who continued HT
use at least until July 2004. Other women in the study
population were excluded for reason of stopping before
August 2003 (n = 2,954), stopping between January 2004
and July 2004 (n = 379), or lacking sufficient follow-up time
(n = 295). Mean age in the index group was 53.9 (SD 5.7)
years; mean age in the reference group was 53.1 (SD 6.6)
years. The difference in age between groups was significant
(P G 0.01) but not considerable.
Prescription of nonhormonal drugs
Population at risk, number of incident cases, incidence rate
(per 100.000 patient-days), and IRR with 95% CI are
presented for the nonhormonal drug classes in Table 1. Also
shown are subanalyses per age category for antidepressants
and per specific type of drug for antidepressants and
osteoporosis prophylaxis and treatment.
Nonhormonal drug prescribing in the index group differed
significantly with the reference group for several drug
classes, including clonidine (IRR 3.48, 95% CI 2.36-5.13),
anxiolytics and sedatives (IRR 1.46, 95% CI 1.15-1.87), and
osteoporosis prophylaxis and treatment (IRR 2.04, 95% CI
1.14-3.66). Overall IRR of antidepressants was borderline
significant (IRR 1.34, 95% CI 0.97-1.86), while overall IRRs
of gabapentin and antipsychotics did not reach statistical
significance.
Point estimates of the IRR in most drug classes did not
differ considerably by age category (data not shown except
for antidepressants). In the antidepressant class, however, a
significantly increased incidence rate for the index group was
found in the age category 40 to 49 years (IRR 2.70, 95% CI
1.41-5.11). Conversely, in the age category 60 to 69 years the
incidence rate for the index group was decreased, albeit
borderline significant (IRR 0.43, 95% CI 0.18-1.05).
Antidepressant use was increased for both tricyclic anti-
depressants and SSRIs, but not for the other types of
antidepressants (including SNRIs and monoamine oxidase
inhibitors). The incidence rate for osteoporosis medication
was only increased for bisphosphonates (IRR 2.54, 95%
CI 1.16-5.55) and calcium supplements (IRR 2.25, 95%
CI 1.11-4.58).
KM curves were plotted for all drug classes; significance
of the log-rank P values corresponded with the significance
of the IRRs for all drug classes. Shown in Figure. 2 are KM
curves for clonidine, anxiolytics and sedatives, and osteopo-
rosis prophylaxis. These KM curves suggest that prescribing
occurs soon after stopping HT. Shown in Figure. 3 are KM
curves for antidepressants, paneled for age categories 40 to
49 years and 60 to 69 years. The difference in antidepressant
prescribing is significant and opposite between the two age
categories.
DISCUSSION
Time-trend analysis on HT prescribing
In agreement with previous studies by our group,9,10 we
found a dramatic and statistically significant decline in
exposure prevalence of HT after publication of the MWS.
This study shows that HT prescription is continuously low
from 2004 up until the end of 2006, confirming that the
decline is sustained. Compared to the decline following the
MWS, the decline following the WHI trial was modest. Other
countries have described a decline in HT prescribing
following the WHI trial, including Australia,25 Canada,26,27
Ireland,28 New Zealand,29 the United Kingdom,30 and the
United States.31<33 Only one of these studies analyzed data
beyond 2004, which also reported the sustained impact on
HT prescribing.33 The response to the MWS is much less
reported in literature. This could be because unlike in the
FIG. 3. Time to antidepressant prescription for patients who stopped HT (solid line) or continued HT (gray line). A: 40-49 years; B: 60-69 years.
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Netherlands, the WHI trial had already portrayed a consid-
erable effect on HT prescribing in most countries, obscuring
an additive effect of the MWS. Still, the Irish study reported
that the decline in HT prescribing after the WHI trial sus-
tained after the MWS.28
Nonhormonal drugs prescription
Women who stopped HT use shortly after the publication
of the MWS in August 2003 were more often prescribed
nonhormonal drugs indicated for treatment of menopausal
symptoms, confirming our hypothesis. Incidence of cloni-
dine, antidepressants (in the age category 40-49 y), anxio-
lytics and sedatives, and osteoporosis prophylaxis and
treatment were all significantly increased in women who
stopped HT compared with women who continued HT.
Survival plots showed that these nonhormonal drugs are
prescribed soon after HT cessation. A US study reported that
approximately half of all women who stopped HT developed
vasomotor, urogenital, or mood-related disorders.32 The study
also found that 60% of all patients with menopausal symp-
toms were treated with nonhormonal therapy, primarily
antidepressants of the SNRI class.32 An Irish study showed
an increase in the prescription rate of bisphosphonates cor-
relating with a decrease in HT prescribing.28
The incidence of antidepressant prescribing for women
stopping HT was significantly increased in the age category
40 to 49 years and borderline significantly decreased in the
age category 60 to 69 years. This is in line with the
conclusions of Cohen et al,13 who found that perimenopausal
depression in younger women can be effectively treated with
estrogen therapy,34 whereas hormonal treatment was not
found to be effective in a trial with older women,35 and those
of Freeman et al,36 who found that depressive symptoms in-
creased during transition to menopause and decreased in
postmenopausal women.
While performing the analyses for this study, we found a
relatively large number of women prescribed both HT and
antidepressant drugs. In 2003, antidepressant drug prevalence
among women using HT was 14.6%, 17.1%, and 14.7% in
women aged 40 to 49, 50 to 59, and 60 to 69 years,
respectively. These prevalences were 11.0%, 11.4%, and
9.8% in the general population (all #2 P G 0.001), based on
IADB data. These data suggest that a subgroup of women in
the menopausal transition phase was not sufficiently treated
with HT alone and needed a combination of antidepressants
and HT. The Bmissed[ symptoms of menopause, such as
sleep disturbances, mood changes, and somatic complaints,37
can play an important role. Further research is needed on
this topic.
Limitations
For our analyses on nonhormonal drug prescribing, we
used strict exclusion criteria. These ensured that our index
group comprised only women who had consistently used HT
up until the publication of the MWS, after which they
stopped, whereas our reference group consisted only of
women who were consistently prescribed HT at least up until
July 2004. A possible limitation of these criteria is that
knowledge of the results of the WHI trial, published in July
2002, may have influenced general practitioners_ or women_s
behavior. However, in The Netherlands, media attention after
the WHI was negligible,9 and this study showed that
influence on HT prescribing behavior was small compared
with that of the MWS. If, alternatively, we had selected
stoppers after the WHI trial, this could have introduced bias
by including many women who did not stop HT because of
their own or their general practitioner_s concerns about the
therapy but for unrelated reasons. Although our strict ex-
clusion criteria may raise concerns over the generalizability
of the results, they increase the internal validity of the study
by accurately focusing on the women of interest.
Our data set consists of drug dispensing data from com-
munity pharmacies. We were therefore unable to include
over-the-counter medication, including complementary and
alternative medicine, in our analysis. This has probably led
to an underestimation in the proportion of nonhormonal
therapies started by women stopping HT. Further research,
preferably interview based, is warranted to investigate the use
of these treatment alternatives.
Our prescription database does not contain information on
indications for drug use and type of prescriber. It would be
interesting to study what drugs women with menopausal
complaints without HT are being prescribed currently; data
on indications for drug use, however, are a prerequisite for
such a study.
Clinical implications
Although this is a descriptive study, we think that a
clinical implication of this study is the concern for adverse
effects associated with the increase in nonhormonal therapies.
Recently, a randomized controlled trial in healthy postmeno-
pausal women found that calcium supplementation was
associated with an increased risk for cardiovascular events.38
Other nonhormonal treatment modalities investigated in this
study are not known for increased risk for cardiovascular
event or cancer when used in therapeutic dosages. However,
other types of adverse effects are well known, including
fatigue, insomnia, nausea, and headaches.39 An implication
of this study is the recommendation for future research to
assess whether the risk-benefit ratio of nonhormonal treat-
ment modalities for menopausal complaints is superior to the
HT used previously.
CONCLUSION
This study shows the dramatic and sustained impact of
two cautioning landmark studies, the WHI trial and the
MWS, on hormone therapy prescribing. HT stoppers recieved
more nonhormonal therapies for menopausal symptoms
compared to those who continued HT, including clonidine;
anxiolytics or sedatives; and osteoporosis prophylaxis and
treatment. Young stoppers (40-49 y) received more anti-
depressants, while older stoppers (60-69 y) recieved less
antidepressants.
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